Live tape
Top 8, mentions 7d15,138NVDA4,219 mentions▲ +0.04GOOGL2,529 mentions▲ +0.04AMD1,898 mentions▲ +0.08SPY1,708 mentions▲ +0.06QQQ1,650 mentions▲ +0.05SPCX1,124 mentions▲ +0.06TSLA1,022 mentions▲ +0.05AAPL988 mentions▲ +0.05

Equity · Healthcare

APVO

NASDAQ

Aptevo Therapeutics (APVO)

1.21 USD −3.20% vs prior close Nov 6, 2026
Aptevo Therapeutics Inc. price graph
63 sessions
5 1 11 Aug 6 Nov

The line runs 4.14 USD on 11 August through 1.21 USD on 6 November, on a scale from 1 to 5. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
2.2M USD
EPS, diluted, year to Dec 2025
−87.27 USD
Avg volume
1.2K

as of Nov 6, 2026

Have Aptevo Therapeutics (APVO) insiders bought or sold shares recently?

APVO has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 6 August 2026.

Form 4

Have Aptevo Therapeutics (APVO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
10 Nov 2025Grant Grady IIIBuy13,51320K USD
13 other filings: grants, exercises, tax withholding and transfers, not trades
Have Aptevo Therapeutics (APVO) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
06 Aug 2026Harsanyi ZsoltDirectorOption exercise400
06 Aug 2026Lamothe Jeffrey G.President and CEOOption exercise961
06 Aug 2026Taylor DaphneSVP, CFOOption exercise638
06 Aug 2026Kwon SoYoungSVP, GC, BD & Corp AffairsOption exercise638
06 Aug 2026Huebner DirkSVP, CMOOption exercise638
06 Aug 2026Huebner DirkSVP, CMOTax withheld156635 USD
06 Aug 2026Grant Grady IIIDirectorOption exercise400
06 Aug 2026White Marvin LExecutive ChairOption exercise1,666
06 Aug 2026White Marvin LExecutive ChairTax withheld4062K USD
06 Aug 2026Abdun-Nabi DanielDirectorOption exercise400
06 Aug 2026Kunz Barbara LopezDirectorOption exercise400
06 Aug 2026Niederhuber JohnDirectorOption exercise400

Showing the 12 most recent of 13 compensation filings in this window. The figures above count all of them.

Which funds hold Aptevo Therapeutics (APVO)?

0 of the 45 institutional funds we track reported a Aptevo Therapeutics position for the quarter ended 31 Dec 2025; the latest of those filings landed 17 Feb 2026.

Form 13F

Which funds hold Aptevo Therapeutics (APVO)?
FundPositionSharesValueShares q/q
Point72 Asset ManagementExited

Have members of Congress traded Aptevo Therapeutics (APVO)?

The most recent congressional trade disclosed in Aptevo Therapeutics is a sale by Steve Cohen (house, TN), dated 24 Jun 2019.

STOCK Act disclosures

Have members of Congress traded Aptevo Therapeutics (APVO)?
TradedMemberTypeAmountFiled after
24 Jun 2019Steve Cohenhouse · Democrat–TNSale470 USD+9 days

What has been filed or recorded for Aptevo Therapeutics (APVO)?

The filings we hold for Aptevo Therapeutics, newest first: 6 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 13 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Aptevo Therapeutics (APVO)?
And
13 Oct 2026Fails to deliverShares failed to deliver4,498 shares8K USD notional · 0.250% of shares out
08 Oct 2026Fails to deliverShares failed to deliver507 shares928 USD notional · 0.028% of shares out
07 Oct 2026Fails to deliverShares failed to deliver2,372 shares4K USD notional · 0.132% of shares out
06 Oct 2026Fails to deliverShares failed to deliver1,775 shares3K USD notional · 0.099% of shares out
30 Sep 2026Fails to deliverShares failed to deliver1,954 shares4K USD notional · 0.108% of shares out
29 Sep 2026Fails to deliverShares failed to deliver1,958 shares4K USD notional · 0.109% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −5.31 USD
30 Jun 2026FinancialsTotal assets14.5M USDat period end
30 Jun 2026FinancialsTotal equity6.0M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −6.41 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −87.27 USD
31 Dec 2025FinancialsNet income−26.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−87.27 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −2.23 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −151.29 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −1,581.81 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −31,460.23 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −357.86 USD

Aptevo Therapeutics (APVO): frequently asked questions

From live data
1.21

What did Aptevo Therapeutics shares close at?

Aptevo Therapeutics closed at 1.21 USD on 6 Nov 2026, down 3.20% on the close before. That is the end-of-day price from Finazon, not a live quote.

2.2M

What is Aptevo Therapeutics’ market cap?

Aptevo Therapeutics is worth 2.2M USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Aptevo Therapeutics insiders bought or sold shares recently?

No Aptevo Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 6 Aug 2026 (SEC Form 4). See Insiders

0 of 45

Which funds own Aptevo Therapeutics?

0 of the 45 funds we track reported a Aptevo Therapeutics position for the quarter ended 31 Dec 2025, per their SEC Form 13F filings. The largest reported position was Point72 Asset Management. See Funds

1 trade

Have members of Congress traded Aptevo Therapeutics?

Yes. 1 trade in Aptevo Therapeutics appears in the congressional disclosures we hold: a sale by Steve Cohen (House, TN) dated 24 Jun 2019, filed 3 Jul 2019. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress

−5.31

When did Aptevo Therapeutics last report earnings?

Aptevo Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −5.31 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. House disclosuresU.S. House of Representatives financial disclosures
  6. SECSEC fails-to-deliver (CNS) data
  7. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  8. SEC EDGARreported earnings figures and scheduled report dates
  9. SEC EDGARValuation computed from SEC EDGAR filings